- Emerging Therapies for Treatment of Hereditary Hemolytic Anemias
-
Education ProgramGeneric 'disconnected' Message
Disclosure:
Terremoto - Consultancy (Includes expert testimony); Terremoto - Research Funding; Alpine - Consultancy (Includes expert testimony); Agios - Research Funding; Agios - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Sobi - Research Funding; Diagonal - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Amgen - Research Funding; Novartis - Research Funding; Novartis - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony); Alnylam - Research Funding; Alnylam - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Vaderis - Consultancy (Includes expert testimony); Vaderis - Research Funding
Inherited
hemolytic anemias are a heterogeneous group of disorders in which overlapping
clinical features have historically complicated diagnosis and management. In
this session, Dr. Khoriaty will highlight the shift from traditional stepwise
testing toward molecular-based diagnosis, emphasizing its central role in
accurate classification and therapeutic decision-making. Using pyruvate kinase
deficiency as a model, he will review the emergence of targeted therapies such
as mitapivat and their impact on hemoglobin levels, hemolysis, and transfusion
burden. He will also discuss current supportive strategies alongside evolving
approaches, including next-generation metabolic therapies and gene-based
interventions. Together, these advances illustrate a broader transition toward
precision medicine aimed at modifying disease biology rather than managing its
complications.
Dr. Shenoy will focus on the treatment of HHAs
with a stem cell transplant, with an intention to cure. While stem cell
transplantation as an intervention is not new, it has been increasingly used
over the recent years to replace the genetically defective erythrocytes with
normal donor-derived erythropoiesis. She will discuss the wide-ranging modern
advances in stem cell transplantation that have facilitated successful outcomes
with low toxicity that have enabled expansion of this treatment modality to include
a variety of human-leukocyte-antigen (HLA) matched and mismatched donors, stem
cell sources, and disease states, even in very young children.
Hereditary
hemolytic anemias (HHAs) have long been managed with supportive interventions,
such as transfusions and splenectomy. This paradigm is now beginning to change.
In this presentation, Dr. Al-Samkari will focus on non-hemoglobinopathy HHAs,
examining the emerging therapeutic landscape through representative cases. He
will highlight pyruvate kinase deficiency as the clearest example of successful
targeted pharmacologic therapy, reviewing the development and clinical impact
of pyruvate kinase activators. He will additionally discuss the broader
potential for metabolic therapies in other HHAs such as membranopathies and
enzymopathies, where early clinical and preclinical data suggest that
modulating red cell energetics or membrane biology may lead to clinical
benefit. Finally, he will look forward to the next frontier of precision
medicine, discussing genetic approaches to fixing the underlying molecular
defect in selected disorders. Although many of these approaches remain
investigational, they signal an important shift toward mechanism-based
treatment.Program
Enter Note
Go to previous page in this tab
Session

